From OncoLog, June 2011, Vol. 56,
Selected Research and Clinical Milestones at MD Anderson 1941–2011
Texas Governor W. Lee “Pappy” O’Daniel signs legislation authorizing the creation of a cancer hospital as part of The University of Texas System.
MD Anderson treats its first patient.
Researchers design and test the first cobalt-60 radiation therapy unit.
Some of the world’s first psychological research and counseling programs for cancer patients begin at MD Anderson.
The first issue of MD Anderson’s newsletter to physicians, now named OncoLog, is published.
Vincristine becomes the first successful chemotherapy for children with inoperable Wilms tumors.
Surgeons begin performing limb-sparing surgery for extremity tumors.
MD Anderson is the first cancer hospital in the U.S. to install “life islands” to protect immunocompromised patients against infections.
C-banding enables scientists to pinpoint the precise location of genes on various chromosomes.
A clinical protocol for vinblastine and bleomycin becomes the first chemotherapy regimen to offer complete remission for patients with testicular cancer.
MD Anderson opens the first Department of Dental Oncology in the U.S.
Clinical studies demonstrate that lumpectomy followed by radiation therapy is as effective as radical mastectomy for breast cancer treatment.
A clinical trial of the mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) regimen for treatment of pediatric patients with brain tumors begins.
The Department of Urology establishes a Section of Sexual Rehabilitation—the first of its kind—to help patients maintain intimacy following cancer treatment.
The first clinical use of liposomes to deliver targeted drug therapy is reported.
Researchers adapt the polymerase chain reaction test to detect lymphoma cells in concentrations as low as 1 lymphoma cell per 1 million blood cells.
MD Anderson opens the country’s first operating room equipped with a linear accelerator to deliver intraoperative radiation therapy.
A landmark study establishes the benefits of administering chemotherapy to shrink breast tumors before surgery and radiation therapy.
Surgeons establish the benefit of surgical resection of multiple brain metastases in some patients.
Researchers pioneer the use of reduced chemotherapy doses for patients also requiring stem cell transplantation, resulting in lower mortality rates.
A miniature multileaf collimator to more precisely shape radiation therapy beams is designed at MD Anderson.
An epidermal growth factor receptor VIII peptide vaccine is developed to treat cerebral tumors.
Researchers report initial clinical results of berubicin, the first blood-brain barrier–penetrating anthracycline for treatment of brain tumors, which was discovered and developed at MD Anderson.
Researchers establish the effectiveness of dasatinib and nilotinib against imatinib-resistant chronic myelocytic leukemia.
MD Anderson opens the largest proton therapy center in the U.S.
Researchers demonstrate the efficacy of intensity-modulated radiation therapy against several types of cancer.
A clinical trial of lenalidomide plus dexamethasone for patients with relapsed multiple myeloma leads to FDA approval of lenalidomide.
Stereotactic body radiation therapy is shown to be an effective treatment for some lung cancer patients.
Researchers report a successful phase III clinical trial of a therapeutic vaccine for follicular lymphoma.
Results from BATTLE, a clinical trial of four drugs (each targeting a different signaling pathway), support the use of biomarkers and personalized therapy for lung cancer.
A phase II study demonstrates that proton therapy with chemotherapy can reduce radiation-related toxicity compared with conventional photon treatment.
For more information, talk to your physician, visit www.mdanderson.org, or call askMDAnderson at 877-632-6789.
Home/Current Issue | Previous Issues | Articles by Topic | Patient Education
About Oncolog | Contact OncoLog | Sign Up for E-mail Alerts
©2013 The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd., Houston, TX 77030
1-877-MDA-6789 (USA) / 1-713-792-3245